GlassScriptPhysician profile
Linette Rivera
NPI 1447485446
$2,032.47
in general payments reported to CMS, 2019-2025
15 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2022: $56.02 · 2023: $318 · 2024: $85.02 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $410.58 | 2019-2022 | |
| Insulet Corporation | $375.17 | 2019-2025 | Omnipod, Omnipod |
| Cequr Corporation | $345.45 | 2025 | Cequr Simplicity |
| Abbvie INC. | $342.44 | 2023-2024 | |
| Amgen INC. | $189.15 | 2025 | Tepezza |
| Tandem Diabetes Care, INC. | $75.39 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $65.37 | 2024-2025 | Cleviprex |
| Abbott Laboratories | $37.92 | 2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $37.33 | 2023 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $33.22 | 2025 | Dexcom G6 Transmitter |
| Alvogen INC | $33.14 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $32.76 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $23.62 | 2025 | Imcivree |
| Fidia Pharma USA INC. | $18.06 | 2025 | |
| Ibsa Pharma INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linette Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.